Results 211 to 220 of about 7,770,494 (359)

From what should we protect future generations: germ-line therapy or genetic screening? [PDF]

, 2003
Pierre Mallia, Henk ten Have
openalex   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

In vivo imaging of molecular-genetic targets for cancer therapy [PDF]

, 2003
Juri G. Gelovani, Ronald G. Blasberg
openalex   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Targeting rare splicing defects: Antisense oligonucleotides offer a therapeutic strategy in FRDA. [PDF]

Mol Ther Nucleic Acids
Kerkhof LMC, Buijsen RAM.
europepmc   +1 more source

Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction

, 2002
Alexander P. Reiner, Susan R. Heckbert, Hans L. Vos, Robert A. S. Ariëns, Rozenn N. Lemaître, Nicholas L. Smith, Thomas Lumley, Thomas D. Rea, Lucia A. Hindorff, Gina D. Schellenbaum, Frits R. Rosendaal, David S. Siscovick, Bruce M. Psaty   +12 more
openalex   +1 more source

Genetic variability: The key problem in the prevention and therapy of RNA‐based virus infections [PDF]

, 2003
Magdalena Figlerowicz, Magdalena Alejska, Anna Kurzyńska‐Kokorniak, Marek Figlerowicz   +3 more
openalex   +1 more source

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Nature Reviews. Cancer, 2016
S. Topalian, J. Taube, R. Anders, D. Pardoll   +3 more
semanticscholar   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec): Bone Marrow Histopathology and Correlation With Genetic Status [PDF]

, 2003
Debra Resta, Martin S. Tallman, Mary Beth Riley, John L. Frater, Brian Druker, LoAnn Peterson, Daina Variakojis, Mary Ann Hrisinko   +7 more
openalex   +1 more source